Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer

Sarah J. Backe 1,2,†, Rebecca A. Sager 1,2,†, Katherine A. Meluni 1,2, Mark R. Woodford 1,2,3,*
Dimitra Bourboulia 1,2,3,* and Mehdi Mollapour 1,2,3,*

1 Department of Urology, SUNY Upstate Medical University, Syracuse, NY 13210, USA; backes@upstate.edu (S.J.B.); sagerr@upstate.edu (R.A.S.); kam445@cornell.edu (K.A.M.); woodform@upstate.edu (M.R.W.); bourmpod@upstate.edu (D.B.)
2 Upstate Cancer Center, Upstate University Hospital, Syracuse, NY 13210, USA
3 Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
* Correspondence: mollapom@upstate.edu
† These authors contributed equally to this work.

Abstract: Heat shock protein-90 (Hsp90) is a ATP-dependent molecular chaperone that is tightly regulated by a group of proteins termed co-chaperones. This chaperone system is essential for the stabilization and activation of many key signaling proteins. Recent identification of the co-chaperones FNIP1, FNIP2, and Tsc1 has broadened the spectrum of Hsp90 regulators. These new co-chaperones mediate the stability of critical tumor suppressors FLCN and Tsc2 as well as the various classes of Hsp90 kinase and non-kinase clients. Many early observations of the roles of FNIP1, FNIP2, and Tsc1 suggested functions independent of FLCN and Tsc2 but have not been fully delineated. Given the broad cellular impact of Hsp90-dependent signaling, it is possible to explain the cellular activities of these new co-chaperones by their influence on Hsp90 function. Here, we review the literature on FNIP1, FNIP2, and Tsc1 as co-chaperones and discuss the potential downstream impact of this regulation on normal cellular function and in human diseases.

Keywords: tuberous sclerosis complex (TSC); Tsc1 (hamartin); Tsc2 (tuberin); heat shock protein 90 (Hsp90); FNIP1; FNIP2; co-chaperones; cancer; renal cell carcinoma; kidney cancer

1. Introduction

Heat shock protein-90 (Hsp90) is a molecular chaperone essential for maintaining signaling competence in eukaryotic cells. Hsp90 is comprised of an N-terminal ATP binding domain, a middle domain for binding “client” proteins, and a site of constitutive dimerization at the carboxy-terminus [1–3]. Hsp90 function is coupled to its ability to bind and hydrolyze ATP and undergo a series of conformational changes known as the “chaperone cycle” [4,5]. This cycle facilitates the maturation and activation of more than 300-client proteins, including kinases, and non-kinases such as steroid hormone receptors, transcription factors, and tumor suppressors [6] (https://www.picard.ch/downloads/Hsp90interactors.pdf, accessed on 12 February 2022). A number of these Hsp90 client proteins participate in oncogenesis, and this chaperone machine is often co-opted by cancers to maintain deregulated signaling pathways and buffer the effect of pathogenic mutations [7–11]. The breadth of signaling pathways mediated by its clients makes Hsp90 an attractive therapeutic target and dozens of Hsp90-directed small molecules have been developed. In fact, there are 14-ATP-competitive Hsp90 inhibitors in ongoing clinical trials in various cancers (www.clinicaltrials.gov, accessed on 1 May 2022) [12].

The binding and dissociation of Hsp90-modulating proteins, termed co-chaperones, tailors Hsp90 to particular clients and provides directionality to the chaperone cycle [13–16]. To date, more than 25 Hsp90 co-chaperones with varying characteristics and classifications...
have been identified. Prior to the recent characterization of the three large co-chaperones Tsc1, FNIP1, and FNIP2 (hereon referred to as FNIP1/2), known Hsp90 regulatory proteins existed within the range of 20–100 kDa [15]. These three large co-chaperones are each approximately 130 kDa [17–21] and were originally identified as stabilizers of specific tumor suppressor proteins implicated in the mTOR pathway [17–19]. The co-chaperone function of FNIP1/2 and Tsc1 gives us an opportunity to reevaluate the previous published work from a new perspective. Here we review the functions and roles of FNIP1/2, and Tsc1 that have been reported, describe their functions as new co-chaperones of Hsp90, and retrospectively evaluate how new functions can help contextualize previous observations. We also review their roles in cancer and cellular response to Hsp90 inhibitors as well as their emerging role in chaperoning of tumor suppressors.

2. FNIP1 and FNIP2

2.1. FNIP1/2 Structure and Function

Folliculin interacting proteins 1 and 2 (FNIP1/2) are named after their first identification in complex with the tumor suppressor folliculin (FLCN) [17,18]. Loss of FLCN function is implicated in Birt-Hogg-Dubé (BHD) syndrome, a hereditary condition characterized by benign fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax, and renal tumors, which are most often of hybrid oncocytic or chromophobe histology [22]. FLCN interacts with FNIP1/2 via its C-terminus, which stabilizes the FLCN protein. This mechanism is supported by the instability of C-terminally truncated FLCN protein products resulting from FLCN mutations identified in BHD [17,18,22,23] and indeed, many of these mutated FLCN proteins fail to associate with FNIPs and are targeted for proteasomal degradation [24]. Recently, portions of the FLCN:FNIP2 structure have been resolved by cryo-EM [25,26]. The structures support previous evidence that FLCN contains a GTPase activating protein (GAP) domain and interacts with FNIP2 through its C-terminal differentially expressed in normal and neoplastic cells (DENN) domain. Additionally, the N-terminal Longin domains of FLCN and FNIP2 proteins also interact, emphasizing the complex nature of the interaction between FLCN and the FNIPs [25,26]. Despite this well-supported finding, the precise mechanism by which FLCN stability is achieved had remained elusive. Our group demonstrated that FLCN is a client of Hsp90 and depends on the co-chaperone activity of FNIP1 and FNIP2 for loading to Hsp90 and thus stability [20].

FNIP1 shares 74% similarity and 49% identity with FNIP2 [18], and the majority of research on FNIPs is exclusive to FNIP1. Initially, FNIP1 was found to be phosphorylated by AMP-activated protein kinase (AMPK) as well as facilitate AMPK-mediated phosphorylation of FLCN [17]. AMPK is a negative regulator of the mTOR nutrient-sensing pathway, and FNIP1 was found to translocate from the cytoplasm to lysosomes under starvation conditions [27], therefore a role for FNIP1 in mTOR signaling was suggested, though direct, mechanistic evidence remains elusive (Figure 1).

2.2. FNIP1 Function in Skeletal Muscle and Adipocytes

One pathway in which the FNIP1-AMPK interaction has been interrogated is skeletal muscle fiber type specification. Broadly, type I muscle fibers are highly aerobic, express elevated levels of myoglobin, and have high mitochondrial function, while type II muscle fibers are comparatively lower in both and favor anaerobic glycolysis [28]. AMPK is known to regulate mitochondrial biogenesis via peroxisome proliferator-activated receptor-γ coactivator-1 α and β (PGC1α/PGC1β) and is activated under low energy conditions to suppress mTOR-dependent ATP utilization [29]. FNIP1−/− mice contain an abundance of type I muscle fibers, similar to mice with gain-of-function mutations in AMPK [30,31]. This suggests that at steady state FNIP1 suppresses AMPK and thus regulates mitochondrial biogenesis. Liu et al. furthered this line of inquiry by demonstrating that miR-499, an intron of the gene encoding the major slow-twitch type I myosin heavy chain (Myh7b), directly targets and inhibits translation of FNIP1 but not FNIP2 [32]. Similar results have been shown for miR-208b [33]. Interestingly, FNIP1-mediated AMPK inhibition can be
reversed by the flavonoid dihydromyricetin, which causes a decrease in FNIP1 expression and reactivates AMPK-mediated mitochondrial biogenesis [34]. These data provide a mechanism that explains the FNIP1-dependent regulation of AMPK in skeletal muscle.

Figure 1. FNIPs and Tsc1 in the mTOR pathway. The mTOR pathway is a cellular signaling hub that integrates signals from several pathways and controls protein synthesis. A simplified schematic representation is shown to highlight the role of the FLCN/FNIPs and TSC complexes as mTOR regulators through GAP activity of RagA/C and Rheb, respectively.

FNIP1 regulation of AMPK may be cell-type dependent however, as recent work has demonstrated that FNIP1 regulates cellular respiration in adipocytes in an AMPK/mTOR independent manner [35]. Specifically, FNIP1 was shown to regulate intracellular Ca²⁺ levels through stabilization of sarcoplasmic reticulum calcium transport ATPase (SERCA) and increasing SERCA Ca²⁺ pump activity. This study also suggested a pivotal role for FNIP1 in regulating metabolism and glucose homeostasis in adipocytes, independent of AMPK/mTOR [35].

2.3. FNIP1 in Oxidative Stress

An interesting perspective on FNIP1 regulation of AMPK activity can be gained through an understanding of the factors governing FNIP1 protein dynamics. Recent work has shown that reductive stress promoted the degradation of FNIP1, but not FNIP2 [36]. The mechanism was traced to the chelation of Zn²⁺ by two reduced Cys residues in
FNIP1, which recruits CUL2\textsuperscript{FEM1B} [36,37], the scaffold and recognition subunits of an E3-ubiquitin ligase complex [38]. Degradation of FNIP1 in this context promotes AMPK-PGC1α-mediated mitochondrial biogenesis to counteract reductive stress [36,37]. Interestingly, loss of FEM1B led to decreased lactate production [36], perhaps as a byproduct of FNIP1-dependent stabilization of FLCN and its recently described tumor suppressive effect on lactate dehydrogenase A [39].

2.4. FNIP1 Function in B-Cell Development

Another striking example of FNIP1 function is in lymphoid differentiation and maturation. Park et al. identified a pre-B cell “checkpoint” where loss of FNIP1 prevents mature B-cell development [40]. These cells were found to be sensitive to nutrient-deprivation-induced apoptosis seemingly due to failure of AMPK to suppress mTOR in the absence of FNIP1 [40]. Interestingly, FNIP1-deficient B-cell progenitors also exhibit elevated TFE3 transcription as well as increased lysosome function and autophagic flux [41]. Similarly, loss of FNIP1 prevents maturation of invariant natural killer T cells and increases their sensitivity to apoptosis [42]. FNIP1 knockout was again determined to cause downstream mTOR activation, though in this case the effect is definitively indirect, as rapamycin treatment was not able to rescue the phenotype [42]. Concurrent research also found a marked pre-B cell blockade and confirmed that the effect stems from caspase activation and intrinsic apoptosis [43]. This effect was also observed in patients, as FNIP1 mutation caused a clinically significant reduction in B cell numbers and hypogammaglobulinemia [44,45]. In addition to B-cell deficiency, FNIP1 loss leads to cardiomyopathy, which phenocopies AMPK gain-of-function mutations, consistent with a failure of FNIP1 to regulate AMPK-mediated signaling [46]. Taken together, these data support a role for FNIP1 as an indirect regulator of mTOR through its suppression of AMPK activity, and likely also via its positive regulation of FLCN [47].

2.5. Role of FNIP1/2 in Transcription

Recent work has also demonstrated the impact of the FLCN-FNIP1/2 system on transcriptional reprogramming. It is well established that loss of FLCN induces nuclear localization of the transcription factors TFE3/TFEB and promotes a gene expression program favorable for tumor growth [41,48–51]. Similarly, it was recently shown that simultaneous deletion of FNIP1/2/2 in a human renal proximal tubular epithelial cell (RPTEC) line induced a TFE3-mediated gene signature [52]. This is in agreement with previous data showing that FLCN-null and FNIP1-null mice developed phenotypically indistinguishable enlarged polycystic kidneys [53,54]. Additionally, loss of either FLCN or FNIP1/2 induced a STAT2-dependent interferon response transcriptional program, though the impact of interferon signaling in FLCN-deficient tumors is unclear [52].

Despite the progress reviewed here, it remains difficult to disentangle the cellular roles of FNIP1/2 in the regulation of AMPK and TFE3 from that of FLCN tumor suppressive function. Given this, it is possible that FNIP1/2-mediated regulation of Hsp90 activity provides a unifying explanation for FNIP-mediated cellular effects.

3. Tsc1

3.1. Structure and Function of the Tsc1/2 Complex

Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic syndrome caused by mutations in either the TSC1 or TSC2 tumor suppressors. In addition to neural associations that include epilepsy, subependymal giant cell astrocytomas (SEGA), intellectual disability, and autism, TSC is also characterized by cutaneous, pulmonary, and renal manifestations, similar to BHD [23,55,56]. These include facial fibrofolliculomas, pulmonary lymphangiomyomatosis, and renal angiomyolipomas (AML). The TSC2 gene was cloned first in 1993 followed by the non-homologous TSC1 gene in 1997 [19,57]. The Tsc1 and Tsc2 proteins, also known as hamartin and tuberin, respectively, were then shown to directly interact and form a complex [58]. The 130 kDa Tsc1 and 200 kDa Tsc2 proteins share no
homology with each other [59]. Recently, partial structures of this complex were resolved by cryo-EM and revealed an elongated structure with a 2:2 stoichiometry. Further, Tsc1 was consistently found to have a coiled-coil domain which mediated Tsc1 dimerization and interaction with Tsc2 in vitro [60–62]. This is in contrast to a previous study using a yeast two-hybrid system which identified Tsc1 residues 302–430 as the critical region for Tsc2 interaction [63]. Tsc2 interaction with Tsc1 was primarily mediated through the N-terminal Tsc2-HEAT repeat domain, which is consistent with previous findings [60,62,63]. Furthermore, Tsc1 was required for Tsc2 maximal GAP activity likely through proper positioning of the Tsc2 catalytic asparagine-thumb [62].

The Tsc1/2 complex was demonstrated to inhibit mTOR signaling through the GAP activity of Tsc2 towards Rheb [64–66] (Figure 1). The effect of Tsc2 was greatly potentiated by the presence of Tsc1. In this TSC complex, Tsc1 has been shown to be important for the stabilization of Tsc2, preventing its interaction with the HERC1 ubiquitin ligase and its ubiquitination [67,68]. Early identification of Tsc1 and Tsc2 in complex and the role of this complex in the mTOR pathway focused a large portion of the TSC literature on this function and does not address separable functions of Tsc1 and Tsc2.

3.2. Separable Functions of Tsc1 and Tsc2

There are a number of differences in Tsc1 and Tsc2 function that have been identified, as well as mTOR-independent functions. Early reports suggested that although Tsc1 and Tsc2 often co-localize, the subcellular locations as well as tissue and organ expression patterns of Tsc1 and Tsc2 are not identical [69]. Germline mutations in TSC1 cause a similar but not identical phenotype to TSC2 mutations in animal models, suggesting commonalities to the pathways involved but some differences as well [70]. Renal tumors developed in heterozygous TSC1 mice at a slower rate than in TSC2+/− mice. In addition to renal cystadenomas, TSC1+/− mice also develop liver hemangiomas, which are more common and more severe in female mice, demonstrating sex-dependent lethality [71]. Concordantly, an analysis of patients in the TOSCA database (TuberOus SClerosis registry to increase disease Awareness) revealed that female patients were significantly more likely to develop renal AML and experience hemorrhage [72]. Sex-dependent and estrogen linked effects exclusive to Tsc1 can also be seen in mammary development. Conditional Tsc1 loss in mammary epithelium impaired mammary development through suppression of Akt, ER, and cell cycle regulators and did not lead to tissue hyperplasia [73]. Moderate overexpression of Tsc1 also enhances overall health and cardiovascular health in an animal model and improves survival only in female mice [74]. Tsc1 and Tsc2 have also been shown to have separable functions in both cell signaling and cell cycle control [75,76]. Milolaza et al. describe the effect of Tsc1 and Tsc2 on the G1 to S phase transition of the cell cycle. Tsc1 and Tsc2 control cell proliferation independent of each other, and only Tsc2 function is affected by p27 expression [75]. Further evidence for separate functions of Tsc1 and Tsc2 comes from microarray and proteomic approaches, which reveal that each TSC gene triggers substantially different cellular responses [77–82].

3.3. mTOR Independent Functions of Tsc1

While the effects of Tsc1 loss are often ascribed to increased mTOR signaling and are at least partially responsive to rapamycin, there are also mTOR independent functions of Tsc1 that have been reported. Tsc1 haploinsufficiency without mTOR activation was shown to lead to renal cyst formation in TSC1+/− mice [83]. It has also recently been demonstrated that p21 activated kinase 2 (PAK2) is an effector of the Tsc1/Tsc2 complex. Loss of either Tsc1 or Tsc2 promotes hyperactivity of PAK2 downstream of Rheb, but independent of mTOR, as demonstrated by insensitivity to rapamycin treatment [84]. Tsc1 and Tsc2 also differentially modulate the cytoskeleton. TSC1−/− and TSC2−/− MEFs demonstrate rapamycin insensitive increase in number and length of cilia [85] whereas only Tsc2 loss promotes an mTOR-dependent pro-migratory phenotype [86]. On the other hand, Tsc1 loss was shown to dysregulate tight junction development in an mTOR independent
manner [87]. Collectively, these studies suggest a role for Tsc1 in cell integrity independent of mTOR.

Furthermore, it has long been observed that clinical features of TSC across multiple organ systems are more severe in patients with mutations in TSC2 than in patients with TSC1 mutations [88–90]. There is a higher incidence of intellectual disability in patients with TSC2 mutations, and it has been suggested that severity of disability may correlate with predicted effects of mutations on Tsc1 and Tsc2 protein [91–93]. Epilepsy generally exhibits an earlier onset and is also more severe as a result of TSC2 mutations [94,95]. Similarly, the mean age at diagnosis for patients with renal AML was lower in patients with TSC2 mutations. Additionally, patients with TSC2 mutations had a higher occurrence of renal AML, multiple renal cysts and polycystic kidney disease compared to patients with TSC1 mutations [72]. In a mouse model, conditional knockout (CKO) of TSC2 in GFAP-positive cells also produces a more severe epilepsy phenotype than TSC1 CKO [96]. Additionally, it has been proposed that perhaps TSC resulting from TSC1 mutation is not less common than TSC2 disease but that it is less frequently diagnosed due to the milder clinical features [97].

Collectively, this evidence suggests a role for Tsc1 outside the TSC complex and mTOR signaling. Due to the described role of Tsc1 in stabilizing Tsc2 and protecting it from ubiquitination we questioned whether this protective role involved molecular chaperones and whether Tsc1 was involved in chaperoning Tsc2. In fact, Tsc2 is a client of Hsp90, and Tsc1 is a co-chaperone [21].

4. Regulation of Hsp90 Chaperone Function by Co-Chaperones

The action of co-chaperones towards Hsp90 generally meets one or more of the following criteria: (1) scaffolding of client proteins to Hsp90 (e.g., Hop, p50Cdc37); (2) modulation of Hsp90 ATPase activity (e.g., Aha1); (3) stabilization of specific chaperone complexes (e.g., p23) and are not themselves dependent on Hsp90 for stability [98]. We have shown that the newly identified large co-chaperones FNIP1/2 and Tsc1 are able to satisfy at least two of these observed co-chaperone functions (Figure 2). Indeed, we have a unique opportunity to advance our understanding of the function and effect of these proteins as we reconcile their known functions with their roles as Hsp90 co-chaperones.

Hsp90-dependent maturation and activation of client proteins relies on a continuum of regulated conformational changes of Hsp90 coupled to ATP hydrolysis. As currently understood, there are several “stages” to a generalized chaperone cycle. Initially, immature clients bind to the early chaperone heat shock protein 70 (Hsp70) and the Hsp70-Hsp90 organizing protein (Hop) forms a bridge to the “open” conformation of Hsp90, allowing the transfer of a client protein to Hsp90 [99]. ATP subsequently binds to the amino-terminal nucleotide binding pocket, and concurrent binding of the Activator of Hsp90 ATPase (Aha1) displaces Hop and induces transient N-domain dimerization, forming the “closed 1” state. Aha1 binds to the N-domain as well as the middle domain of Hsp90 and greatly increases the weak intrinsic ATPase activity of Hsp90 [100]. Interaction of the co-chaperone p23 with the N-domain of Hsp90 displaces Aha1 and stabilizes the “closed and twisted” conformation (closed 2). This allows completion of ATP hydrolysis, followed by release of a mature client protein and the return of Hsp90 to the open conformation [101–103].

The complement of co-chaperones that regulate Hsp90 during a single chaperone cycle is largely dependent on the individual requirements of the client protein [104]. For example, kinase clients are loaded to Hsp90 by the co-chaperone Cdc37, a decelerator of Hsp90 ATPase activity, and protein phosphatase 5 (PP5)-mediated dephosphorylation of Cdc37 is required for their release [105,106]. Alternatively, overexpression of Aha1 greatly decreases the folding of CFTR by accelerating the rate of Hsp90 ATP hydrolysis [107–109]. Similarly, steroid hormone receptors prefer a slower chaperone cycle and require the co-chaperone p23, which is known to decelerate the action of Hsp90 [5,110–112]. In fact, GR itself is capable of modulating the conformation of Hsp90 such that Hsp90 ATPase activity
decreases [113], demonstrating the degree of specificity that can be achieved by modulation of Hsp90 complexes [15].

**Figure 2. The Hsp90 chaperone cycle.** Open Hsp90 is dimerized only through contacts in the CTD. ATP binding and an ordered series of conformational changes allow Hsp90 to adopt a closed conformation, which is N-terminally dimerized. ATP hydrolysis leads Hsp90 to return to the open conformation and begins another chaperone cycle. Throughout the chaperone cycle co-chaperones bind to Hsp90 and regulate its function. PTM of Hsp90 and PTM of co-chaperones provide further regulation of the chaperone cycle.

5. FNIP1/2 and Tsc1: New Co-Chaperones of Hsp90

Recent reports from Mollapour’s group demonstrated that the tumor suppressors FLCN and Tsc2 are Hsp90 clients [20,21]. As FNIP1/2 and Tsc1, respectively, have established roles as guardians of these tumor suppressors [17,18,67,68], it follows that there may be a role for molecular chaperones in mediating FLCN and Tsc2 stability. Indeed FNIP1/2 and Tsc1 both interact with Hsp90 and Hsp70, as well as with overlapping complements of Hsp90 co-chaperones including PP5, Cdc37, Hop, and p23 and behave as Hsp90 co-chaperones [20,21] (Figure 3). These reports also demonstrate a role for these new co-chaperones in regulating both kinase and non-kinase clients, as well as provide clues to their chronology in the overall chaperone cycle.

FNIP1 and Tsc1 share a number of striking similarities in their actions as co-chaperones. Both FNIP1 and Tsc1 exhibit complex binding to Hsp90; contacts are made using multiple domains of these co-chaperones as well as multiple domains of Hsp90. The most well characterized interactions thus far however are that of FNIP1 and Tsc1 binding the Hsp90 middle domain via their carboxy-termini. It is through this interaction that they decelerate Hsp90 ATPase activity and compete with the accelerating co-chaperone Aha1 for Hsp90 occupancy. In addition to increasing the dwell time of ATP (and thus client proteins)
on Hsp90, interaction with these large co-chaperones also increases Hsp90 binding to its ATP-competitive inhibitors [20,21,114].

Figure 3. FNIPs and Tsc1 co-chaperone interaction network. Hsp90 co-chaperones are represented by colored circles. Interactions between co-chaperones are denoted by colored lines. FNIP1 interactions are colored red; FNIP2, yellow; Tsc1, blue; other, gray.

While the overall pattern of how FNIP1 and Tsc1 interact with Hsp90 is similar there are key differences between them. The C-terminal fragment of Tsc1 (Tsc1-D) binds to Hsp90 with higher affinity than does the C-terminal fragment of FNIP1 (FNIP1-D). Similarly, Tsc1-D is a potent inhibitor of Hsp90 ATPase activity and very effectively competes with Aha1 for Hsp90 binding as evidenced by in vitro competition experiments. FNIP1 and Tsc1 can also be distinguished by the complement of co-chaperones with which they interact therefore, providing clues to their distinct roles in the chaperone cycle. While neither is found in complex with Aha1, Tsc1 is able to interact with PP5 and Cdc37, whereas FNIP1/2 can additionally be found in complexes containing p23 and Hop (Figure 3). This may demonstrate some promiscuity of FNIPs, but likely reflects the necessity for FNIPs to work in concert with other co-chaperones, while Tsc1 may be capable of modulating Hsp90 independently. This potentially explains the observation that Tsc1 is a much more potent decelerator of Hsp90 ATP hydrolysis than FNIP1/2 [20,21,114]. Interestingly, Tsc1 also inhibits the ATPase activity of another molecular chaperone, Hsp70, in vitro [115]. Whether FNIPs share this function remains unknown.

Despite their shared role in facilitating chaperoning of both kinase and non-kinase clients, FNIP1/2 and Tsc1 over-expression and deletion have different effects. Non-kinase clients are destabilized upon knockdown/knockout of FNIP1/2 or Tsc1 and stabilized with overexpression of the co-chaperones. Interestingly, FNIP1/2 knockdown or overexpression affects the kinase clients in a comparable manner as the non-kinase clients, however overexpression or absence of Tsc1 both negatively affect kinase client stability [20,21]. This may be due to the participation of FNIP1/2 with a variety of chaperone complexes, whereas the semi-exclusive nature of Tsc1 co-chaperone activity disrupts the delicate balance of Hsp90 co-chaperone dynamics.

5.1. FNIP1/2 and Tsc1 in the Chaperone Cycle

This large body of work on co-chaperone dynamics allows us to propose a model of FNIPs and Tsc1 co-chaperones in the Hsp90 chaperone cycle. Our previous work demonstrates that FNIPs and Tsc1 interact with Hsp70 in addition to Hsp90, and FNIP1 and Tsc1 are essential for scaffolding FLCN and Tsc2, respectively, to Hsp90 (Figure 4A,B) [20,21,23]. Subsequent ATP binding triggers conformational changes leading to the N-terminally dimerized ‘closed’ conformation of Hsp90 (Figure 4C) [116–119]. We have previously shown that Tsc1 and FNIP1 are not found in complex with Aha1 and that phosphorylation of Aha1-Y223 displaces Tsc1 from Hsp90 (Figure 4D) [20,21,109]. p23 is a late-acting co-chaperone that locks Hsp90 in the closed conformation to allow proper client matu-
We propose that p23:FNIP1:FNIP2 holds the matured client in its active conformation until there is a signal for client release, resetting Hsp90 for another cycle (Figure 4G,H).

Figure 4. FNIPs and Tsc1 in the Hsp90 chaperone cycle. (A) FNIPs and Tsc1 co-chaperones scaffold a client from Hsp70 to Hsp90. (B) Hsp70 dissociates from the complex. (C) ATP binding triggers Hsp90 conformational rearrangements resulting in the ‘closed’ conformation. (D) Aha1 phosphorylated at Y223 displaces FNIPs/Tsc1 co-chaperones from the Hsp90 complex and promotes ATP hydrolysis to ADP + Pi. (E) p23 binds and stabilizes the closed conformation of Hsp90. (F) FNIP co-chaperones bind to the Hsp90:client:p23 complex to promote client maturation. (G) The complex dissociates releasing the mature client. (H) Hsp90 is reset to begin another cycle.

5.2. FNIPs, Tsc1 and the Chaperone Code

Hsp90 and its co-chaperones’ functions are heavily regulated by post-translational modifications (PTM), collectively known as the ‘chaperone code’ [128,129]. An additional layer of Hsp90 regulation via FNIP1 is provided through FNIP1 post-translational modification. Recent work by our group identified a series of serine residues (S938, S939, S941, S946, and S948) in the Hsp90-binding region of the FNIP1 carboxy-terminus that are phosphorylated in a relay manner by casein-kinase 2 (CK2) [114]. This sequential phosphorylation promotes FNIP1 interaction with Hsp90 while dephosphorylation of these residues by the Hsp90 co-chaperone PP5 disrupts the Hsp90-FNIP1 complex. Furthermore, stepwise phosphorylation of FNIP1 provides gradual inhibition of Hsp90 ATPase activity and therefore increased activity of a subset of both kinase and non-kinase clients [114].

These new co-chaperones also affect Hsp90 binding to its ATP-competitive inhibitors. Generally, there is an inverse relationship between the rate of ATP hydrolysis and the ability of Hsp90 to bind ATP-competitive inhibitors [20,21,109]. Overexpression of FNIP1/2 or
Tsc1 decreases Hsp90 ATPase activity, thus increasing Hsp90 binding to its inhibitors. As expected, Hsp90 inhibitor binding is decreased upon knockdown of FNIP1/2 or loss of Tsc1 \[20,21,114,130\]. Interestingly, approximately 15% of bladder cancers have loss-of-function mutations in Tsc1. Tsc1 loss causes hypo-acetylation of Hsp90 on K407 and K419 leading to decreased binding of Hsp90 to its inhibitors, demonstrating another mechanism of Tsc1-mediated regulation of Hsp90 [130]. The precise mechanism of how Tsc1 loss compromises Hsp90 acetylation remains unknown, however it is important to note that Hsp90 acetylation can be restored by histone-deacetylase (HDAC) inhibition, sensitizing TSC1-null cells to Hsp90 inhibitors [130].

Targeting Hsp90 in cancer cell lines induces apoptosis, and Hsp90 inhibitors have been found to preferentially accumulate in cancer cells versus normal cells [131–135]. FNIP1/2 were found overexpressed in cancer cell lines originating from several different tissues, and knockdown decreased sensitivity of these cancers to Hsp90 inhibition [20]. This increased expression of FNIP1/2 provides one potential mechanism to explain the tumor selectivity of Hsp90 inhibitors. Similarly, bladder cancer cells lacking functional Tsc1 fail to accumulate Hsp90 inhibitors and are less sensitive to Hsp90 inhibition than those with wild-type Tsc1 [130].

Collectively, these studies provide support for a new functional role for the tumor suppressor Tsc1 and FNIP1/2 as co-chaperones of Hsp90. As Hsp90 co-chaperones the protective function of Tsc1 and the FNIPs goes beyond mediating stability of Tsc2 and FLCN, respectively, and provides insight into a larger role for these proteins in the cellular context.

6. A New Perspective: FNIPs, Tsc1, and mTOR

Early connection of FNIP1/2 and Tsc1 to the mTOR nutrient-sensing pathway has narrowed the focus of research conducted on these proteins. Recent research has demonstrated that FNIP1/2 and Tsc1 act as co-chaperones of Hsp90. This allows us to reevaluate the previous published work with a new perspective.

6.1. FNIP1/2 Co-Chaperone Activity Contributes to mTOR Regulation

As reviewed in this text, FNIP1 negatively regulates AMPK activity. Since the α and γ subunits of AMPK are known clients of Hsp90 [136], the effect of FNIP1 on AMPK could be mediated through the Hsp90 chaperone (Figure 5). In support of this idea, microarray data show that B220⁺CD43⁺ pre-B cells from FNIP1⁻/⁻ mice demonstrate a dramatic increase in expression of AMPK-responsive genes [40]. These data would suggest a role for FNIP1 in activation of mTOR, however we posit that this mechanism may actually be more complicated. First, mTOR is also an Hsp90 client protein [137] and will be subject to the influence of Hsp90 co-chaperones as with any other client protein. Second, it is likely that loss of FLCN is actually responsible for mTOR activation, as is suggested by Baba et al., whose data show that the induction of mTOR is mild in FNIP1⁻/⁻ mice as compared to FLCN⁻/⁻ and that FNIP1 deletion fails to phenocopy BHD syndrome [17,43,54]. Concordantly, FNIP co-chaperone activity toward FLCN can explain the observation that non-degradable FNIP2 enhances FLCN expression and thus suppresses tumorigenesis in a BHD mouse xenograft model [138]. Together, these data highlight that the co-chaperone activity of FNIP1/2 is essential for FLCN-mediated mTOR suppression, but also underscore our inability to reconcile this observation with the current understanding of FNIP1/2 function.

6.2. Co-Chaperone Activity of Tsc1 in Regulation of mTOR

The newly identified role for Tsc1 as an Hsp90 co-chaperone may help clarify some of the phenotypic differences as a result of Tsc1 versus Tsc2 mutation. Due to its function as a co-chaperone, Tsc1 loss would trigger effects on many cellular pathways, not just mTOR signaling. This could explain the finding of renal cyst formation in TSC1⁺/⁻ mice, as well as provide insight into the pro-migratory phenotype seen only in TSC2⁻/⁻ MEFs [83,86]. Furthermore, Tsc1 loss, but not Tsc2 loss, causes hypo-acetylation of Hsp90 further demon-
strating a role for Tsc1 independent of both Tsc2 and mTOR [130]. The loss of Tsc1 has a dramatic negative effect on Hsp90 kinase and non-kinase clients, including Tsc2. It is reasonable therefore that loss of Tsc1 co-chaperone activity manifests itself independently of the mTOR pathway.

Figure 5. Hsp90 clients in the mTOR pathway. A schematic representation of the mTOR pathway highlighting the components that are Hsp90 clients (red).

As discussed above, Tsc1 loss has long been known to lead to a less severe phenotype than Tsc2 loss both in patients as well as animal models [88–90,94–97]. Canonically, Tsc2 loss leads to upregulation of mTOR signaling due to release of the inhibitory signal from Tsc2-Rheb [139]. Activation and phosphorylation of mTOR and its downstream targets as well as other pathway components such as Akt has been shown to be dependent on Hsp90; in fact, many mTOR pathway components are clients of Hsp90 [140–143] (Figure 5). Activation of the mTOR pathway is therefore dependent on proper function of the Hsp90 chaperone system. Perhaps the milder phenotype seen with Tsc1 loss is a result of the loss of co-chaperone activity toward Hsp90. Upon Tsc1 loss, Tsc2 is destabilized leading to
increased mTOR activity; however, the other proteins in the mTOR pathway that are Hsp90 clients would also be destabilized, potentially mitigating the downstream effect.

Rapalogs, such as sirolimus and everolimus, are rapamycin derivatives that are commonly used to treat patients with BHD and TSC. Armed with the information of the role of Hsp90 in BHD and TSC, perhaps preclinical examination of Hsp90 inhibitors in combination with rapalogs is warranted. In fact, Hsp90 inhibitors have been shown to synergize with PI3K/Akt/mTOR inhibitors in preclinical studies for the treatment of various cancers [144–146]. In line with this, Di Nardo et al. identified the heat-shock machinery as an exploitable target in Tsc2-deficient neurons [147]. Accordingly, one study has evaluated mTOR and Hsp90 inhibitors in combination in TSC1 or TSC2 deficient cancer models. Unfortunately, the results were inconsistent between cell line and mouse xenograft models, as synergism between Hsp90 inhibitor (GB) and mTOR inhibitors (Torin2, rapamycin) in cell lines did not translate to increased efficacy over monotherapy in xenograft models [148]. Taken together, these studies demonstrate the potential therapeutic benefit of co-targeting Hsp90 and mTOR in BHD and TSC patients. However, further investigation is needed.

7. Specialized Function of FNIP1/2 and Tsc1: Chaperoning Tumor Suppressors

An important and perhaps specialized role for these new Hsp90 co-chaperones is in the chaperoning of tumor suppressors. FLCN and Tsc2 are additions to the growing list of tumor suppressors that interact with Hsp90. The transcription factor p53 was the first reported tumor suppressor client of Hsp90 [149–152]. Since 1996, 17 functional Hsp90 interactions with both kinase and non-kinase tumor suppressors have been discovered (Table 1) [20,21,149,153–163]. Furthermore, several tumor suppressors including, VHL, BDC2, LKB1, p53, FLCN and LATS1/2 were found to interact with Hsp90 co-chaperones including, Hop, p23, Hsp110, Cdc37, PP5, and CHIP [20,23,150,154,159,160,164–167]. As FNIP1/2 and Tsc1 scaffold the tumor suppressors FLCN and Tsc2 to Hsp90, it follows that these co-chaperones may participate in the chaperoning of additional Hsp90-dependent tumor suppressor clients. In line with this notion, Tsc1 was identified as a genetic interactor with VHL in HeLa cells highlighting the need for further exploration in this area [168].

Table 1. Relationships of known tumor suppressor-Hsp90 interactions.

| Tumor Suppressor Gene | Relationship to Hsp90 | References |
|-----------------------|-----------------------|------------|
| ATM Kinase            | Client                | [153,169]  |
| BMP1R1A               | Client                | [161]      |
| BRCA1/2               | Client                | [158,170,171] |
| DBC2                  | Client                | [159]      |
| FBXW7                 | Interactor            | [161]      |
| FLCN                  | Client                | [20,23]    |
| IRF1                  | Client                | [156]      |
| LATS1/2               | Client                | [162,167,172] |
| LKB1                  | Client                | [154,173,174] |
| NDRG2                 | Interactor            | [163]      |
| SYK                   | Client                | [155,175]  |
| TNAIP3                | Interactor            | [161,167]  |
| TP53                  | Client                | [8,103,149–152,164–166,177–187] |
| TSC1                  | Co-chaperone          | [21,130]   |
| TSC2                  | Client                | [21]       |
| VHL                   | Client                | [160,188]  |
| WT1                   | Client                | [157]      |

Additionally, there is new evidence supporting a compensatory mechanism between FNIP1/2 and Tsc1 co-chaperone activity. FLCN traditionally requires interaction via its C-terminus to FNIP1/2 to mediate its stability. Tsc1, however, is capable of interacting with a truncated FLCN mutant and supporting a low level of expression in the absence of FNIP1/2 binding [23]. Unexpectedly, the truncated FLCN-L460QsX25 was still able
to interact with Hsp90 even though it did not bind to its loading co-chaperone FNIP1. Overexpression of Tsc1, but not FNIP1 was capable of stabilizing expression of the mutant FLCN. Notably, Tsc1 interaction with Tsc2 was compromised in this model resulting in loss of Tsc2 tumor suppressive function. Loss of such a compensatory mechanism may also explain why deletion of FNIP1 synergized with TSC1 deletion to activate mTOR and subsequently resulted in accelerated renal cyst formation in mice [189]. These findings necessitate investigation into how these large co-chaperones mediate chaperoning of tumor suppressors and the impact of tumor suppressor mutations on this relationship.

8. Conclusions

Hsp90 is an important component of the cellular homeostatic machinery and is regulated by post-translational modification and interaction with co-chaperones. There are more than 25 known co-chaperones that serve several functions including modulating Hsp90 conformations, loading client proteins to Hsp90, and modifying the rate of ATP hydrolysis. New data has identified newly characterized roles for three proteins, FNIP1, FNIP2 and Tsc1, as large co-chaperones of Hsp90. Though these proteins have established roles in the regulation of tumor suppressor proteins FLCN and Tsc2, it seems that many of their other ascribed functions are potentially explained at least in part by their effect on Hsp90. A more thorough understanding of the action and interplay of these new, large co-chaperones may unveil clues that will aid in developing the next generation of cancer therapeutics.

Author Contributions: Conceptualization, M.M.; writing—original draft preparation, S.J.B., R.A.S. and M.R.W.; writing—review and editing, S.J.B., R.A.S., M.R.W., D.B. and M.M.; visualization, S.J.B. and K.A.M.; supervision, M.M.; funding acquisition, M.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partly supported with funds from National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM139584 (M.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by Carol M. Baldwin Breast Cancer Fund (M.M.), SUNY Upstate Medical University, Upstate Foundation (M.M.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We are grateful to W. Marston Linehan & Len Neckers (Urologic Oncology Branch, NCI, USA), David J Kwiatkowski (Harvard Medical School, USA) and Chris Prodromou (University of Sussex, UK) for their valuable discussion.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Prodromou, C.; Roe, S.M.; O’Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90, 65–75. [CrossRef]
2. Wegele, H.; Muschler, P.; Bunck, M.; Reinstein, J.; Buchner, J. Dissection of the contribution of individual domains to the ATPase mechanism of Hsp90. J. Biol. Chem. 2003, 278, 39303–39310. [CrossRef] [PubMed]
3. Schopf, F.H.; Biebl, M.M.; Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 2017, 18, 345–360. [CrossRef] [PubMed]
4. Panaretou, B.; Prodromou, C.; Roe, S.M.; O’Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998, 17, 4829–4836. [CrossRef] [PubMed]
5. Prodromou, C. The ‘active life’ of Hsp90 complexes. Biochim. Biophys. Acta 2012, 1823, 614–623. [CrossRef]
6. Prodromou, C.; Bjorklund, D.M. Advances towards Understanding the Mechanism of Action of the Hsp90 Complex. Biomolecules 2022, 12, 600. [CrossRef] [PubMed]
7. Tsutsumi, S.; Beebe, K.; Neckers, L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol. 2009, 5, 679–688. [CrossRef] [PubMed]
8. Boysen, M.; Kityk, R.; Mayer, M.P. Hsp70- and Hsp90-Mediated Regulation of the Conformation of p53 DNA Binding Domain and p53 Cancer Variants. Mol. Cell 2019, 74, 831–843. [CrossRef]
9. Calderwood, S.K.; Gong, J. Heat Shock Proteins Promote Cancer: It’s a Protection Racket. Trends Biochem. Sci. 2016, 41, 311–323. [CrossRef]

10. Xu, Y.; Singer, M.A.; Lindquist, S. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl. Acad. Sci. USA 1999, 96, 109–114. [CrossRef] [PubMed]

11. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, 555–561. [CrossRef]

12. Xiao, Y.; Liu, Y. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014. Curr. Drug Targets 2020, 21, 302–317. [CrossRef]

13. Cox, M.B.; Johnson, J.L. The Role of p23, Hop, Immunophilins, and Other Co-chaperones in Regulating Hsp90 Function. Methods Mol. Biol. 2011, 787, 45–66. [CrossRef] [PubMed]

14. Ratzke, C.; Hellenkamp, B.; Hugel, T. Four-colour FRET reveals directionality in the Hsp90 multicomponent machinery. Nat. Commun. 2014, 5, 4192. [CrossRef] [PubMed]

15. Sahasrabudhe, P.; Rohrberg, J.; Biebl, M.M.; Rutz, D.A.; Buchner, J. The Plasticity of the Hsp90 Co-chaperone System. Mol. Cell 2017, 67, 947–961.e5. [CrossRef] [PubMed]

16. Dahiya, V.; Rutz, D.A.; Moessmann, P.; Muhlhofer, M.; Lawatscheck, J.; Rief, M.; Buchner, J. The switch from client holding to folding in the Hsp70/Hsp90 chaperone machineries is regulated by a direct interplay between co-chaperones. Mol. Cell 2022. [CrossRef] [PubMed]

17. Baba, M.; Hong, S.B.; Sharma, N.; Warren, M.B.; Nickerson, M.L.; Iwamatsu, A.; Esposito, D.; Gillette, W.K.; Hopkins, R.F.; 3rd; Hartley, J.L.; et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. USA 2006, 103, 15552–15557. [CrossRef] [PubMed]

18. Hasumi, H.; Baba, M.; Hong, S.B.; Hasumi, Y.; Huang, Y.; Yao, M.; Valera, V.A.; Linehan, W.M.; Schmidt, L.S. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008, 415, 60–67. [CrossRef]

19. van Slegtenhorst, M.; de Hoogt, R.; Hermans, C.; Nellist, M.; Janssen, B.; Verhoef, S.; Lindhout, D.; van den Ouweland, A.; Halley, D.; Young, J.; et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277, 805–808. [CrossRef] [PubMed]

20. Woodford, M.R.; Dunn, D.M.; Blanden, A.R.; Capriotti, D.; Loiselle, D.; Prodromou, C.; Panaretou, B.; Hughes, P.F.; Smith, A.; Ackerman, W.; et al. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nat. Commun. 2016, 7, 12037. [CrossRef] [PubMed]

21. Woodford, M.R.; Sager, R.A.; Marris, E.; Dunn, D.M.; Blanden, A.R.; Murphy, R.L.; Rensing, N.; Shapiro, O.; Panaretou, B.; Prodromou, C.; et al. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 2017, 36, 3650–3665. [CrossRef] [PubMed]

22. Schmidt, L.S.; Linehan, W.M. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Trends Genet. 2020, 36, 558–569. [CrossRef] [PubMed]

23. Sager, R.A.; Woodford, M.R.; Shapiro, O.; Mollapour, M.; Bratslavsky, G. Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dube: Chaperones in pathogenesis. Oncotarget 2015, 6, 22220–22229. [CrossRef] [PubMed]

24. Clausen, L.; Stein, A.; Gronbaek-Thygesen, M.; Nygaard, L.; Soltoft, C.L.; Nielsen, S.V.; Lisby, M.; Ravid, T.; Lindorff-Larsen, K.; Hartmann-Petersen, R. Folliculin variants linked to Birt-Hogg-Dube syndrome are targeted for proteasomal degradation. PLoS Genet. 2020, 16, e1009187. [CrossRef] [PubMed]

25. Lawrence, R.E.; Fromm, S.A.; Fu, Y.; Yokom, A.L.; Kim, D.J.; Thelem, A.M.; Young, L.N.; Lim, C.Y.; Samelson, A.J.; Hurley, J.H.; et al. Structural mechanism of a Rag GTPase activation checkpoint by the lysosomal folliculin complex. Science 2019, 366, 971–977. [CrossRef] [PubMed]

26. Shen, K.; Rogala, K.B.; Chou, H.T.; Huang, R.K.; Yu, Z.; Sabatini, D.M. Cryo-EM Structure of the Human FLCN-FNIP2-Rag-Ragulator Complex. Cell 2019, 179, 1319–1329.e8. [CrossRef] [PubMed]

27. Meng, J.; Ferguson, S.M. GATOR1-dependent recruitment of FLCN-FNIP to lysosomes coordinates Rag GTPase heterodimer nucleotide status in response to amino acids. J. Cell Biol. 2018, 217, 2765–2776. [CrossRef] [PubMed]

28. Schiaffino, S.; Reggiani, C. Fiber types in mammalian skeletal muscles. Physiol. Rev. 2011, 91, 1447–1531. [CrossRef] [PubMed]

29. Hardie, D.G. Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc. Nutr. Soc. 2011, 70, 92–99. [CrossRef] [PubMed]

30. Reyes, N.L.; Banks, G.B.; Tsang, M.; Margineantu, D.; Gu, H.; Djukovic, D.; Chan, J.; Torres, M.; Liggitt, H.D.; Hirenallur, S.D.; et al. Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. Proc. Natl. Acad. Sci. USA 2015, 112, 424–429. [CrossRef] [PubMed]

31. Xiao, L.; Liu, J.; Sun, Z.; Yin, Y.; Mao, Y.; Xu, D.; Liu, L.; Xu, Z.; Guo, Q.; Ding, C.; et al. AMPK-dependent and -independent coordination of mitochondrial function and muscle fiber type by FNIP1. PLoS Genet. 2021, 17, e1009488. [CrossRef] [PubMed]

32. Liu, J.; Liang, X.; Zhou, D.; Lai, L.; Xiao, L.; Liu, L.; Fu, T.; Kong, Y.; Zhou, Q.; Vega, R.B.; et al. Coupling of mitochondrial function and skeletal muscle fiber type by a miR-499/Fnip1/AMPK pathway. EMBO Mol. Med. 2016, 8, 1212–1228. [CrossRef] [PubMed]

33. Fu, L.; Wang, H.; Liao, Y.; Zhou, P.; Xu, Y.; Zhao, Y.; Xie, S.; Zhao, S.; Li, X. miR-208b modulating skeletal muscle development and energy homeostasis through targeting distinct targets. RNA Biol. 2020, 17, 743–754. [CrossRef] [PubMed]

34. Zhou, Q.; Gu, Y.; Lang, H.; Wang, X.; Chen, K.; Gong, X.; Zhou, M.; Ran, L.; Zhu, J.; Mi, M. Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1282–1291. [CrossRef]
35. Yin, Y.; Xu, D.; Mao, Y.; Xiao, L.; Sun, Z.; Liu, J.; Zhou, D.; Xu, Z.; Liu, L.; Fu, T.; et al. FNIP1 regulates adipocyte browning and systemic glucose homeostasis in mice by shaping intracellular calcium dynamics. *J. Exp. Med.* 2022, 219, e20212491. [CrossRef]

36. Manford, A.G.; Rodriguez-Perez, F.; Shih, K.Y.; Shi, Z.; Berdan, C.A.; Choe, M.; Titov, D.V.; Nomura, D.K.; Rape, M. A Cellular Mechanism to Detect and Alleviate Reductive Stress. *Cell* 2020, 183, 46–61. [CrossRef]

37. Manford, A.G.; Mena, E.L.; Shih, K.Y.; Gee, C.L.; McMinimy, R.; Martinez-Gonzalez, B.; Sherriff, R.; Lew, B.; Zoltek, M.; Rodriguez-Perez, F.; et al. Structural basis and regulation of the reductive stress response. *Cell* 2021, 184, 5375–5390.e16. [CrossRef]

38. Cai, W.; Yang, H. The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. *Cell Div.* 2016, 11, 7. [CrossRef]

39. Woodford, M.R.; Baker-Williams, A.J.; Sager, R.A.; Backe, S.J.; Blanden, A.R.; Hashimi, F.; Kancherla, P.; Gori, A.; Loiselle, D.R.; Castelli, M.; et al. The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. *Nat. Struct. Mol. Biol.* 2021, 28, 662–670. [CrossRef]

40. Park, H.; Staehling, K.; Tsang, M.; Appleby, M.W.; Brunkow, M.E.; Margineantu, D.; Hockenbery, D.M.; Habib, T.; Liggitt, H.D.; Carlson, G.; et al. Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. *Immunity* 2012, 36, 769–781. [CrossRef]

41. Ramirez, J.A.; Iwata, T.; Park, H.; Tsang, M.; Kang, J.; Cui, K.; Kwong, W.; James, R.G.; Baba, M.; Schmidt, L.S.; et al. Folliculin Interacting Protein 1 Maintains Metabolic Homeostasis during B Cell Development by Modulating AMPK, mTORC1, and TFEB. *J. Immunol.* 2019, 203, 2899–2908. [CrossRef]

42. Park, H.; Tsang, M.; Irritani, B.M.; Bevan, M.J. Metabolic regulator Fnip1 is crucial for nKt lymphocyte development. *Proc. Natl. Acad. Sci. USA* 2014, 111, 7066–7071. [CrossRef]

43. Baba, M.; Keller, J.R.; Sun, H.W.; Resch, W.; Kuchen, S.; Suh, H.C.; Hasumi, H.; Hasumi, Y.; Kieffer-Kwon, K.R.; Gonzalez, C.G.; et al. The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development. *Blood* 2012, 120, 1254–1261. [CrossRef]

44. Niehues, T.; Ozgur, T.T.; Bickes, M.; Waldmann, R.; Schoning, J.; Brasen, J.; Hagel, C.; Ballmaier, M.; Klusmann, J.H.; Niedermayer, A.; et al. Mutations of the gene FNIP1 associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and pre-excitation syndrome. *Eur. J. Immunol.* 2020, 50, 1078–1080. [CrossRef]

45. Saettini, F.; Poli, C.; Vengoechea, J.; Bonanomi, S.; Orellana, J.C.; Fazio, G.; Rodriguez, F.H.; Noguera, L.P.; Booth, C.; Carlson, G.; et al. Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. *Immunity* 2012, 36, 769–781. [CrossRef]

46. Siggs, O.M.; Stockenhuber, A.; Deobagkar-Lele, M.; Bull, K.R.; Crockford, T.L.; Kingston, B.L.; Crawford, G.; Anzilotti, C.; Jarur-Chamy, V.; et al. Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. *Blood* 2013, 117, 493–499. [CrossRef]

47. El-Houjeiri, L.; Possik, E.; Vijayaraghavan, T.; Paquette, M.; Martina, J.A.; Kazan, J.M.; Ma, E.H.; Jones, R.; Blanchette, P.; et al. Folliculin impairs breast tumor and polycystic kidneys. *J. Natl. Cancer Inst.* 2015, 107, 140–154. [CrossRef]

48. El-Houjeiri, L.; Biondini, M.; Paquette, M.; Kuasne, H.; Pacis, A.; Park, M.; Siegel, P.M.; Pause, A. Folliculin impairs breast tumor and polycystic kidneys. *J. Natl. Cancer Inst.* 2015, 107, 140–154. [CrossRef]

49. El-Houjeiri, L.; Biondini, M.; Paquette, M.; Kuasne, H.; Pacis, A.; Park, M.; Siegel, P.M.; Pause, A. Folliculin impairs breast tumor and polycystic kidneys. *J. Natl. Cancer Inst.* 2015, 107, 140–154. [CrossRef]

50. Endoh, M.; Furihata, M.; Hong, S.B.; Tessarollo, L.; Haines, D.C.; Southon, E.; Patel, V.; Igarashi, P.; Alvord, W.G.; Leighty, R.; et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in collaboration with Fln. *Proc. Natl. Acad. Sci. USA* 2015, 112, E1624–E1631. [CrossRef]

51. Hong, S.B.; Valera, V.A.; Baba, M.; Schmidt, L.S.; Linehan, W.M. Inactivation of the FLCN tumor suppressor gene induces translational activity by increasing its nuclear localization. *Eur. J. Immunol.* 2020, 50, 1078–1080. [CrossRef]

52. Baba, M.; Keller, J.R.; Sun, H.W.; Resch, W.; Kuchen, S.; Suh, H.C.; Hasumi, H.; Hasumi, Y.; Kieffer-Kwon, K.R.; Gonzalez, C.G.; et al. The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development. *Blood* 2012, 120, 1254–1261. [CrossRef]

53. Hasumi, H.; Baba, M.; Hasumi, Y.; Lang, M.; Huang, Y.; Oh, H.F.; Matsuo, M.; Merino, M.J.; Yao, M.; Ito, Y.; et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in collaboration with Fln. *Proc. Natl. Acad. Sci. USA* 2015, 112, E1624–E1631. [CrossRef]

54. Baba, M.; Furihata, M.; Hong, S.B.; Tessarollo, L.; Haines, D.C.; Southon, E.; Patel, V.; Igarashi, P.; Alvord, W.G.; Leighty, R.; et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in collaboration with Fln. *Proc. Natl. Acad. Sci. USA* 2015, 112, E1624–E1631. [CrossRef]

55. Henske, E.P.; Jozwiak, S.; Kingswood, J.C.; Sampson, J.R.; Thiele, E.A. Tuberous sclerosis complex. *J. Clin. Investig.* 2008, 120, 2899–2908. [CrossRef]

56. Woodford, M.R.; Backe, S.J.; Sager, R.A.; Bourboulia, D.; Bratslavsky, G.; Mollapour, M. The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dube and Tuberous Sclerosis Complex Syndromes. *Urol. Oncol.* 2021, 39, 322–326. [CrossRef]
57. European Chromosome 16 Tuberous Sclerosis. C. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993, 75, 1305–1315. [CrossRef]

58. van Sleutenhorst, M.; Nellist, M.; Nagelkerken, B.; Cheadle, J.; Snell, R.; van den Ouweland, A.; Reuser, A.; Sampson, J.; Halley, D.; van der Sluijs, P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. *Hum. Mol. Genet.* 1998, 7, 1053–1057. [CrossRef]

59. Huang, J.; Manning, B.D. The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. *Biochem. J.* 2008, 412, 179–190. [CrossRef]

60. Ramlaul, K.; Fu, W.; Li, H.; de Martin Garrido, N.; He, L.; Trivedi, M.; Cui, W.; Aylett, C.H.S.; Wu, G. Architecture of the Tuberous Sclerosis Protein Complex. *J. Mol. Biol.* 2021, 433, 166743. [CrossRef]

61. Fitzian, K.; Bruckner, A.; Brohee, L.; Zech, R.; Antoni, C.; Kiontke, S.; Gasper, R.; Linard Matos, A.L.; Beel, S.; Wilhelm, S.; et al. TSC1 binding to lysosomal PIPs is required for TSC complex translocation and mTORC1 regulation. *Mol. Cell* 2021, 81, 2705–2721.e8. [CrossRef]

62. Yang, H.; Yu, Z.; Chen, X.; Li, J.; Li, N.; Cheng, J.; Gao, N.; Yuan, H.X.; Ye, D.; Guan, K.L.; et al. Structural insights into TSC complex assembly and GAP activity on Rheb. *Nat. Commun.* 2021, 12, 339. [CrossRef]

63. Hodges, A.K.; Li, S.; Maynard, J.; Parry, L.; Braverman, V.; Cheadle, J.P.; DeClue, J.E.; Sampson, J.R. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. *Hum. Mol. Genet.* 2001, 10, 2899–2905. [CrossRef]

64. Tee, A.R.; Fingar, D.C.; Manning, B.D.; Kwiatkowski, D.J.; Cantley, L.C.; Blenis, J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. *Proc. Natl. Acad. Sci. USA* 2002, 99, 13571–13576. [CrossRef]

65. Garami, A.; Zwartkruis, F.J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Koszma, S.C.; Hafen, E.; Bös, J.L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by Tsc1 and 2. *Mol. Cell* 2003, 11, 1457–1466. [CrossRef]

66. Tee, A.R.; Manning, B.D.; Roux, P.P.; Cantley, L.C.; Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr. Biol.* 2003, 13, 1259–1268. [CrossRef]

67. Benvenuto, G.; Li, S.; Brown, S.J.; Braverman, R.; Vass, W.C.; Cheadle, J.P.; Halley, D.J.; Sampson, J.R.; Wiesenecke, R.; DeClue, J.E. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. *Oncogene* 2000, 19, 6306–6316. [CrossRef]

68. Chong-Kopera, H.; Inoki, K.; Li, Y.; Zhu, T.; Garcia-Gonzalo, F.R.; Rosa, J.L.; Guan, K.L. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. *J. Biol. Chem.* 2006, 281, 8313–8316. [CrossRef]

69. Fukuda, T.; Kobayashi, T.; Momose, S.; Yasui, H.; Hino, O. Distribution of Tsc1 protein detected by immunohistochemistry in various normal rat tissues and the renal carcinomas of Eker rat: Detection of limited colocalization with Tsc1 and Tsc2 gene products in vivo. *Lab. Invest.* 2000, 80, 1347–1359. [CrossRef]

70. Kobayashi, T.; Minowa, O.; Sugitani, Y.; Takai, S.; Mitani, H.; Kobayashi, E.; Noda, T.; Hino, O. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. *Proc. Natl. Acad. Sci. USA* 2001, 98, 8762–8767. [CrossRef]

71. Kwiatkowski, D.J.; Zhang, H.; Bandura, J.L.; Heiberger, K.M.; Glogauer, M.; el-Hashemite, N.; Onda, H. A mouse model of Tsc1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. *Hum. Mol. Genet.* 2002, 11, 525–534. [CrossRef] [PubMed]

72. Kingswood, J.C.; Belousova, E.; Benedik, M.P.; Carter, T.; Cottin, V.; Curatolo, P.;Cartolino, P.; Dahlin, M.; D’Amato, L.; Beaure d’Augeres, G.; Rasch, R.; Antoni, C.; Zech, R.; et al. TSC1 activates TGF-beta-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition. *Dev. Cell* 2020, 52, 876–887. [CrossRef]

73. Qin, Z.; Zheng, H.; Zhou, L.; Ou, Y.; Huang, B.; Yan, B.; Qin, Z.; Yang, C.; Su, Y.; Bai, X.; et al. Tsc1 deficiency impairs mammary development in mice by suppression of AKT, nuclear ERalpha, and cell-cycle-driving proteins. *Sci. Rep.* 2016, 6, 19587. [CrossRef]

74. Zhang, H.M.; Diaz, V.; Walsh, M.E.; Zhang, Y. Moderate lifelong overexpression of tuberous sclerosis complex 1 (TSC1) improves health and survival in mice. *Proc. Natl. Acad. Sci. USA* 2017, 114, 7834–7839. [CrossRef]

75. Miloloza, A.; Kubista, M.; Rosner, M.; Hengstschlager, M. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation. *J. Neuropathol. Exp. Neurol.* 2002, 61, 154–163. [CrossRef]

76. Thien, A.; Pretzelt, M.T.; Holzwarth, B.; Klasinger, K.; Kuper, I.; Boehler, C.; Sonntag, A.G.; Ruf, S.; Maerz, L.; Nitschke, R.; et al. TSC1 activates TGF-beta-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition. *Dev. Cell* 2015, 32, 617–630. [CrossRef]

77. Hengstschlager, M.; Rosner, M.; Fountoulakis, M.; Lupec, G. The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: A proteomic approach. *Int. J. Oncol.* 2005, 27, 831–838. [CrossRef]

78. Rosner, M.; Freiling, A.; Lupec, G.; Hengstschlager, M. The tuberous sclerosis genes, TSC1 and TSC2, trigger different gene expression responses. *Int. J. Oncol.* 2005, 27, 1411–1424. [CrossRef]

79. Dalal, J.S.; Winden, K.D.; Salussolia, C.L.; Sundberg, M.; Singh, A.; Pham, T.T.; Zhou, P.; Pu, W.T.; Miller, M.T.; Sahin, M. Loss of Tsc1 in cerebellar Purkinje cells induces transcriptional and translation changes in FMRP target transcripts. *eLife* 2021, 10, e67399. [CrossRef]
80. Liang, Z.; Zhang, Q.; Zhang, Z.; Sun, L.; Dong, X.; Li, T.; Tan, L.; Xie, X.; Sun, L.; Zhao, Y. The Development and Survival of Thymic Epithelial Cells Require TSC1-Dependent Negative Regulation of mTORC1 Activity. J. Immunol. 2021, 207, 2039–2050. [CrossRef]

81. Liu, Y.D.; Ma, M.Y.; Hu, X.B.; Yan, H.; Zhang, Y.K.; Yang, H.X.; Feng, J.H.; Wang, L.; Zhang, H.; Zhang, B.; et al. Brain Proteomic Profiling in Intractable Epilepsy Caused by TSC1 Truncating Mutations: A Small Sample Study. Front. Neurol. 2020, 11, 475. [CrossRef] [PubMed]

82. Kumar, P.; Zadjalii, F.; Yao, Y.; Siroky, B.; Astrinidis, A.; Gross, K.W.; Bissler, J.J. Tsc Gene Locus Disruption and Differences in Renal Epithelial Extracellular Vesicles. Front. Physiol. 2021, 12, 630933. [CrossRef] [PubMed]

83. Wilson, C.; Bonnet, C.; Guy, C.; Idziaszczyk, S.; Colley, J.; Humphreys, V.; Maynard, J.; Sampson, J.R.; Cheadle, J.P. Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1−/− mice. Cancer Res. 2006, 66, 7934–7938. [CrossRef]

84. Alves, M.M.; Fuhler, G.M.; Queiroz, K.C.; Scholma, J.; Goorden, S.; Anink, J.; Spek, C.A.; Hoogeveen-Westerveld, M.; Bruno, M.J.; Nellist, M.; et al. PKA2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. Sci. Rep. 2015, 5, 14534. [CrossRef] [PubMed]

85. Hartman, T.R.; Liu, D.; Zilfou, J.T.; Robb, V.; Morrison, T.; Watznick, T.; Henske, E.P. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum. Mol. Genet. 2009, 18, 151–163. [CrossRef]

86. Goncharova, E.A.; James, M.L.; Kudryashova, T.V.; Goncharov, D.A.; Kudryashova, T.V.; Tumor suppressors TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported. Hum. Genet. 2013, 132, 55–66. [CrossRef] [PubMed]

87. Lai, M.; Zou, W.; Han, Z.; Zhou, L.; Qiu, Z.; Chen, J.; Zhang, S.; Lai, P.; Li, K.; Zhang, Y.; et al. Tsc1 regulates tight junction independent of mTORC1. Proc. Natl. Acad. Sci. USA 2011, 118, e2020891118. [CrossRef]

88. Dabora, S.L.; Jozwiak, S.; Franz, D.N.; Roberts, P.S.; Nieto, A.; Chung, J.; Choy, Y.S.; Reeve, M.P.; Thiele, E.; Egelhoff, J.C.; et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 2001, 68, 64–80. [CrossRef]

89. Curatolo, P.; Moavero, R.; Roberto, D.; Graziola, F. Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. Semin. Pediatr. Neurosurg. 2015, 22, 259–273. [CrossRef]

90. Sancak, O.; Nellist, M.; Goedbloed, M.; Elfferich, P.; Wouters, C.; Maat-Kievit, A.; Zonnenberg, B.; Verhoef, S.; Halley, D.; van den Ouweland, A.; van Huffelen, A.C.; et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1−/− mice. Cancer Res. 2021, 81, 630933. [CrossRef] [PubMed]

91. Jones, A.C.; Daniells, C.E.; Snell, R.G.; Tachataki, M.; Idziaszczyk, S.A.; Krawczak, M.; Sampson, J.R.; Cheadle, J.P. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet. 1997, 6, 2155–2161. [CrossRef]

92. Niida, Y.; Wakisaka, A.; Tsuji, T.; Yamada, H.; Kuroda, M.; Mitani, Y.; Okumura, A.; Yokoi, A. Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported. J. Hum. Genet. 2013, 58, 216–225. [CrossRef]

93. Wong, H.T.; McCartney, D.L.; Lewis, J.C.; Sampson, J.R.; Howe, C.J.; de Vries, P.J. Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins. J. Med. Genet. 2015, 52, 815–822. [CrossRef] [PubMed]

94. Jansen, F.E.; Braams, O.; Vincken, K.L.; Algra, A.; Anbeek, P.; Jennekens-Schinkel, A.; Halley, D.; Zonnenberg, B.A.; van den Ouweland, A.; van Huffelen, A.C.; et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology 2008, 70, 908–915. [CrossRef]

95. Kothare, S.V.; Singh, K.; Chalifoux, J.R.; Staley, B.A.; Weiner, H.L.; Menzer, K.; Devinsky, O. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 2014, 55, 1025–1029. [CrossRef]

96. Zeng, L.H.; Rensing, N.R.; Zhang, B.; Gutmann, D.H.; Gambello, M.J.; Wong, M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet. 2011, 20, 445–454. [CrossRef]

97. Langkau, N.; Martin, N.; Brandt, R.; Zugge, K.; Quast, S.; Wiegele, G.; Jauch, A.; Rehm, M.; Kuhl, A.; Mack-Vetter, M.; et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/TSC2 frequency ratios. Eur. J. Pediatr. 2002, 161, 393–402. [CrossRef]

98. Dean, M.E.; Johnson, J.L. Human Hsp90 co-chaperones: Perspectives on tissue-specific expression and identification of co-chaperones with similar in vivo functions. Cell Stress Chaperones 2021, 26, 3–13. [CrossRef]

99. Wang, R.Y.; Noddings, C.M.; Kirschke, E.; Myasnikov, A.G.; Johnson, J.L.; Agard, D.A. Structure of Hsp90-Hsp70-Hop-GR reveals the Hsp90 client-loading mechanism. Nature 2022, 601, 460–464. [CrossRef]

100. Li, J.; Richter, K.; Reinstein, J.; Buchner, J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat. Struct. Mol. Biol. 2013, 20, 326–331. [CrossRef]

101. Liu, Y.D.; Ma, M.Y.; Hu, X.B.; Yan, H.; Zhang, Y.K.; Yang, H.X.; Feng, J.H.; Wang, L.; Zhang, H.; Zhang, B.; et al. Brain Proteomic Profiling in Intractable Epilepsy Caused by TSC1 Truncating Mutations: A Small Sample Study. Front. Neurol. 2020, 11, 475. [CrossRef] [PubMed]

102. Wandinger, S.K.; Richter, K.; Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283, 18473–18477. [CrossRef] [PubMed]

103. Langkau, N.; Martin, N.; Brandt, R.; Zugge, K.; Quast, S.; Wiegele, G.; Jauch, A.; Rehm, M.; Kuhl, A.; Mack-Vetter, M.; et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/TSC2 frequency ratios. Eur. J. Pediatr. 2002, 161, 393–402. [CrossRef]
103. Lopez, A.; Daihya, V.; Delhommel, F.; Freiburger, L.; Stehle, R.; Asami, S.; Rutz, D.; Blair, L.; Buchner, J.; Sattler, M. Client binding shifts the populations of dynamic Hsp90 conformations through an allosteric network. Sci. Adv. 2021, 7, eabl2795. [CrossRef]
104. Biebl, M.M.; Riedl, M.; Buchner, J. Hsp90 Co-chaperones Form Plastic Genetic Networks Adapted to Client Maturatiation. Cell Rep. 2020, 32, 10863. [CrossRef] [PubMed]
105. Vaughan, C.K.; Mollapour, M.; Smith, J.R.; Truman, A.; Hu, B.; Good, V.M.; Panaretou, B.; Neckers, L.; Clarke, P.A.; Workman, P.; et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 2008, 31, 886–895. [CrossRef] [PubMed]
106. Sager, R.A.; Dushukyan, N.; Woodford, M.; Mollapour, M. Structure and function of the co-chaperone protein phosphatase 5 in cancer. Cell Stress Chaperones 2020, 25, 383–394. [CrossRef]
107. Wang, X.; Venable, J.; LaPointe, P.; Hutt, D.M.; Koulov, A.V.; Coppinger, J.; Gurkan, C.; Kellner, W.; Matteson, J.; Plutner, H.; et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127, 803–815. [CrossRef]
108. Koulov, A.V.; LaPointe, P.; Lu, B.; Razvi, A.; Coppinger, J.; Dong, M.Q.; Matteson, J.; Laister, R.; Arrowsmith, C.; Yates, J.R., 3rd; et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining human disease cystic fibrosis. Mol. Biol. Cell 2010, 21, 871–884. [CrossRef]
109. Dunn, D.M.; Woodford, M.R.; Truman, A.W.; Jensen, S.M.; Schulman, J.; Caza, T.; Remillard, T.C.; Loiselle, D.; Wolfgeher, D.; Blagg, B.S.; et al. C-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Rep. 2015, 12, 1006–1018. [CrossRef]
110. Siligardi, G.; Hu, B.; Panaretou, B.; Piper, P.W.; Pearl, L.H.; Prodromou, C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem. 2004, 279, 51989–51998. [CrossRef]
111. Rohl, A.; Tippel, E.; Bender, E.; Schmid, A.B.; Richter, K.; Madl, T.; Buchner, J. Hop/Sti1 phosphorylation inhibits its co-chaperone function. EMBO Rep. 2015, 16, 240–249. [CrossRef]
112. Rohl, A.; Wengler, D.; Madl, T.; Lagleder, S.; Tippel, F.; Herrmann, M.; Hendrix, J.; Richter, K.; Hack, G.; Schmid, A.B.; et al. Hsp90 regulates the dynamics of its cochaperone Sti1 and the transfer of Hsp70 between modules. Nat. Commun. 2015, 6, 6655. [CrossRef] [PubMed]
113. Lorenz, O.R.; Freiburger, L.; Rutz, D.A.; Krause, M.; Zierer, B.K.; Alvira, S.; Cuellar, J.; Valpuesta, J.M.; Madl, T.; Sattler, M.; et al. Modulation of the Hsp90 chaperone cycle by a stringent client protein. Mol. Cell 2014, 53, 941–953. [CrossRef]
114. Sager, R.A.; Woodford, M.R.; Backe, S.J.; Makedon, A.M.; Baker-Williams, A.J.; DiGregorio, B.T.; Loiselle, D.R.; Haystead, T.A.; Zachara, N.E.; Prodromou, C.; et al. Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Rep. 2019, 26, 1344–1356.e1345. [CrossRef] [PubMed]
115. Nataraajan, N.; Shaik, A.; Thirunavukkarasu, V. Recombinant Tumor Suppressor TSC1 Differentially Interacts with Escherichia coli DnaK and Human HSP70. ACS Omega 2020, 5, 19131–19139. [CrossRef] [PubMed]
116. Hessling, M.; Richter, K.; Buchner, J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 2009, 16, 287–293. [CrossRef]
117. Dickler, M.; Hessling, M.; Ratzke, C.; Buchner, J.; Hugel, T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nat. Struct. Mol. Biol. 2009, 16, 281–286. [CrossRef]
118. Prodromou, C.; Pearl, L.H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 2003, 3, 301–323. [CrossRef]
119. Shiu, A.K.; Harris, S.F.; Southworth, D.R.; Agard, D.A. Structural Analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127, 329–340. [CrossRef]
120. Noddings, C.M.; Wang, R.Y.; Johnson, J.L.; Agard, D.A. Structure of Hsp90-p23-GR reveals the Hsp90 client-remodelling mechanism. Nature 2022, 601, 465–469. [CrossRef]
121. Ali, M.M.; Roe, S.M.; Vaughan, C.K.; Meyer, P.; Panaretou, B.; Piper, P.W.; Prodromou, C.; Pearl, L.H. Crystal structure of an Hsp90-nucleotide-p23/Sha1 closed chaperone complex. Nature 2006, 440, 1013–1017. [CrossRef] [PubMed]
122. Blacklock, K.; Verkhivker, G.M. Differential modulation of functional dynamics and allosteric interactions in the Hsp90-cochaperone complexes with p23 and Aha1: A computational study. PLoS ONE 2013, 8, e71936. [CrossRef] [PubMed]
123. Cane, L.Q.; Lavery, D.N.; Sin, S.; Spanjaard, E.; Brooke, G.N.; Tilman, J.D.; Abrao, A.; Gaughan, L.; Robson, C.N.; Heer, R.; et al. The co-chaperone p23 promotes prostate cancer motility and metastasis. Mol. Oncol. 2015, 9, 295–308. [CrossRef]
124. Martinez-Yamout, M.A.; Venkitakrishnan, R.P.; Preece, N.E.; Kroon, G.; Wright, P.E.; Dyson, H.J. Localization of sites of interaction between p23 and Hsp90 in solution. J. Biol. Chem. 2006, 281, 14457–14464. [CrossRef]
125. McLaughlin, S.H.; Sobott, F.; Yao, Z.P.; Zhang, W.; Nielsen, P.R.; Grossmann, J.G.; Laue, E.D.; Robinson, C.V.; Jackson, S.E. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 2006, 356, 746–758. [CrossRef] [PubMed]
126. Richter, K.; Walter, S.; Buchner, J. The Co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J. Mol. Biol. 2004, 342, 1403–1413. [CrossRef]
127. Woo, S.H.; An, S.; Lee, H.C.; Jin, H.O.; Seo, S.K.; Yoo, D.H.; Lee, K.H.; Hong, S.I.; et al. A truncated form of p23 down-regulates telomerase activity via disruption of Hsp90 function. J. Biol. Chem. 2009, 284, 30871–30880. [CrossRef] [PubMed]
128. Backe, S.J.; Sager, R.A.; Woodford, M.R.; Makedon, A.M.; Mollapour, M. Post-translational modifications of Hsp90 and translating the chaperone code. J. Biol. Chem. 2020, 295, 11099–11117. [CrossRef]
129. Nitika; Porter, C.M.; Truman, A.W.; Truttmann, M.C. Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code. J. Biol. Chem. 2020, 295, 10689–10708. [CrossRef]
130. Woodford, M.R.; Hughes, M.; Sager, R.A.; Backe, S.J.; Baker-Williams, A.J.; Bratalsky, M.S.; Jacob, J.M.; Shapiro, O.; Wong, M.; Bratalsky, G.; et al. Mutation of the co-chaperone Tscl in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity. *Oncotarget* 2019, 10, 5824–5834. [CrossRef]

131. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformity of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature* 2003, 425, 407–410. [CrossRef] [PubMed]

132. Woodford, M.R.; Truman, A.W.; Dunn, D.M.; Jensen, S.M.; Cotran, R.; Bullard, R.; Abouelleil, M.; Beebe, K.; Wolfgheger, D.; Wierzbicki, S.; et al. Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. *Cell Rep.* 2016, 14, 872–884. [CrossRef] [PubMed]

133. Mollapour, M.; Bourboulia, D.; Beebe, K.; Woodford, M.R.; Polier, S.; Hoang, A.; Chelluri, R.; Li, Y.; Guo, A.; Lee, M.J.; et al. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. *Mol. Cell* 2014, 53, 317–329. [CrossRef] [PubMed]

134. Bisht, K.S.; Bradbury, C.M.; Mattson, D.; Kaushal, A.; Sowers, A.; Markovina, S.; Ortiz, K.L.; Sieck, L.K.; Isaacs, J.S.; Brechbuhl, M.W.; et al. Geldanamycin-dependent Hsp90 inhibition as an anticancer strategy. *Nat. Rev. Cancer* 2003, 3, 894–899.

135. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. *Nat. Rev. Cancer* 2010, 10, 537–549. [CrossRef] [PubMed]

136. Zhang, L.; Yi, Y.; Guo, Q.; Sun, Y.; Ma, S.; Xiao, S.; Geng, J.; Zheng, Z.; Song, S. Hsp90 interacts with AMPK and mediates acetyl-CoA carboxylase phosphorylation. *Cell Signal.* 2012, 24, 859–865. [CrossRef]

137. Moulick, K.; Ahn, J.H.; Zong, H.; Rodina, A.; Cerchietti, L.; Gomes DaGama, E.M.; Caldas-Lopes, E.; Beebe, K.; Perna, F.; Hatzis, K.; et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nat. Chem. Biol.* 2011, 7, 818–826. [CrossRef]

138. Nagashima, K.; Fukushima, H.; Shimizu, K.; Yamada, A.; Hidaka, M.; Hasumi, H.; Ikebe, T.; Fukumoto, S.; Okabe, K.; Inuzuka, H. Nutrient-induced FNIP degradation by SCFbeta-TRCP regulates FLCN complex localization and promotes renal cancer progression. *Oncotarget* 2017, 8, 9947–9960. [CrossRef]

139. Inoki, K.; Li, Y.; Xu, T.; Guan, K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev.* 2003, 17, 1829–1834. [CrossRef] [PubMed]

140. Zhang, L.; Yi, Y.; Guo, Q.; Sun, Y.; Ma, S.; Xiao, S.; Geng, J.; Zheng, Z.; Song, S. Hsp90 interacts with AMPK and mediates acetyl-CoA carboxylase phosphorylation. *Cell Signal.* 2012, 24, 859–865. [CrossRef]

141. Takai, H.; Xie, Y.; de Lange, T.; Pavletich, N.P. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. *Genes Dev.* 2010, 24, 2019–2030. [CrossRef] [PubMed]

142. Acquaviva, J.; He, S.; Zhang, C.; Jimenez, J.P.; Nagai, M.; Sang, J.; Sequeira, M.; Smith, D.L.; Ogawa, L.S.; Inoue, T.; et al. FGFR3 translocations in bladder cancer: Differential sensitivity to HSP90 inhibition based on drug metabolism. *Mol. Cancer Res.* 2015, 13, 284–295. [CrossRef] [PubMed]

143. Takai, H.; Xie, Y.; de Lange, T.; Pavletich, N.P. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. *Genes Dev.* 2010, 24, 2019–2030. [CrossRef] [PubMed]

144. Giulino-Roth, L.; van Besien, H.J.; Dalton, T.; Totonchy, J.E.; Rodina, A.; Taldone, T.; Bolaender, A.; Erdjument-Bromage, H.; Sadek, J.; Chadburn, A.; et al. Inhibition of Hsp90 Suppresses PI3K/PIKT/MTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. *Mol. Cancer Ther.* 2017, 16, 1779–1790. [CrossRef]

145. Solarova, Z.; Mojzis, J.; Solar, P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). *Int. J. Oncol.* 2015, 46, 907–926. [CrossRef]

146. Di Nardo, A.; Lenoel, I.; Winden, K.D.; Ruhmkorf, A.; Modi, M.E.; Barrett, L.; Erkan-Herbst, E.; Venugopalan, P.; Behne, R.; Lopes, C.A.M.; et al. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia. *Cell Rep.* 2017, 20, 1779–1790. [CrossRef]

147. Solarova, Z.; Mojzis, J.; Solar, P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). *Int. J. Oncol.* 2015, 46, 907–926. [CrossRef]
Biomolecules 2022, 12, 928

154. Boudeau, J.; Deak, M.; Lawlor, M.A.; Morrice, N.A.; Alessi, D.R. Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. *Biochem. J.* 2003, 370, 849–857. [CrossRef]

155. Walter, R.; Fan, K.T.; Doebele, C.; Comoglio, F.; Tomoka, K.; Bohnenberger, H.; Young, R.M.; Jacobs, L.; Keller, U.; Bonig, H.; et al. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. *Blood* 2017, 129, 598–608. [CrossRef]

156. Bansal, H.; Bansal, S.; Rao, M.; Foley, K.P.; Sang, J.; Proia, D.A.; Blackman, R.K.; Ying, W.; Barsoum, J.; Baer, M.R.; et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. *Blood* 2010, 116, 4591–4599. [CrossRef]

157. Ichikawa, T.; Shanab, O.; Nakahata, S.; Manachai, N.; Ono, M.; Iha, H.; Shimoda, K.; Morishita, K. Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2(low) ATL and various cancer cells. *Biochim. Biophys. Acta Mol. Cell Res.* 2020, 1867, 118615. [CrossRef] [PubMed]

158. Noguchi, M.; Yu, D.; Hirayama, R.; Ninomiya, Y.; Sekine, E.; Kubota, N.; Ando, K.; Okayasu, R. Inhibition of homologous recombination repair in irradiated tumour cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. *Biochem. Biophys. Res. Commun.* 2006, 351, 658–663. [CrossRef]

159. Manjarrez, J.R.; Sun, L.; Prince, T.; Matts, R.L. Hsp90-dependent assembly of the DBC2/RhoBTB2-Cullin3 E3-ligase complex. *PLoS ONE* 2014, 9, e90054. [CrossRef]

160. McCellan, A.J.; Scott, M.D.; Frydman, J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. *Cell* 2005, 121, 739–748. [CrossRef]

161. King, F.W.; Wawrzynow, A.; Hohfeld, J.; Zylicz, M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. *EMBO J.* 2001, 20, 6297–6305. [CrossRef] [PubMed]

162. Shen, J.P.; Zhao, D.; Sasik, R.; Luebeck, J.; Birmingham, A.; Bojorquez-Gomez, A.; Licon, K.; Klepper, K.; Pekin, D.; Beckett, A.N.; et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. *Nat. Methods* 2017, 14, 573–576. [CrossRef]

163. Boudeau, J.; Deak, M.; Lawlor, M.A.; Morrice, N.A.; Alessi, D.R. Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. *Biochem. J.* 2003, 370, 849–857. [CrossRef]

164. Nokin, M.J.; Durieux, F.; Peixoto, P.; Chiavarina, B.; Peulen, O.; Blomme, A.; Baer, M.R.; et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. *Blood* 2010, 116, 4591–4599. [CrossRef]

165. Bansal, H.; Bansal, S.; Rao, M.; Foley, K.P.; Sang, J.; Proia, D.A.; Blackman, R.K.; Ying, W.; Barsoum, J.; Baer, M.R.; et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. *Blood* 2010, 116, 4591–4599. [CrossRef]

166. Nony, P.; Gaude, H.; Rossel, M.; Fournier, L.; Rouault, J.P.; Billaud, M. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. *Oncogene* 2012, 31, 1582–1591. [CrossRef]

167. Shen, L.J.; Sun, H.W.; Chai, Y.Y.; Jiang, Q.Y.; Zhang, J.; Li, W.M.; Xin, S.J. The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. *Front. Oncol.* 2021, 11, 80412. [CrossRef] [PubMed]
177. Dahiya, V.; Agam, G.; Lawatscheck, J.; Rutz, D.A.; Lamb, D.C.; Buchner, J. Coordinated Conformational Processing of the Tumor Suppressor Protein p53 by the Hsp70 and Hsp90 Chaperone Machineries. *Mol. Cell* 2019, 74, 816–830.e817. [CrossRef] [PubMed]

178. Fukumoto, R.; Kiang, J.G. Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation. *Radiat. Res.* 2011, 176, 333–345. [CrossRef] [PubMed]

179. Giustiniani, J.; Daire, V.; Cantaloube, I.; Durand, G.; Pous, C.; Perdiz, D.; Baillet, A. Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53. *Cell Signal.* 2009, 21, 529–539. [CrossRef]

180. Hagn, F.; Lagleder, S.; Retzlaff, M.; Rohrberg, J.; Demmer, O.; Richter, K.; Buchner, J.; Kessler, H. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. *Nat. Struct. Mol. Biol.* 2011, 18, 1086–1093. [CrossRef]

181. Li, D.; Marchenko, N.D.; Moll, U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. *Cell Death Differ.* 2011, 18, 1904–1913. [CrossRef] [PubMed]

182. Nagata, Y.; Anan, T.; Yoshida, T.; Mizukami, T.; Taya, Y.; Fujiwara, T.; Kato, H.; Saya, H.; Nakao, M. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association. *Oncogene* 1999, 18, 6037–6049. [CrossRef] [PubMed]

183. Park, S.J.; Borin, B.N.; Martinez-Yamout, M.A.; Dyson, H.J. The client protein p53 adopts a molten globule-like state in the presence of Hsp90. *Nat. Struct. Mol. Biol.* 2011, 18, 537–541. [CrossRef] [PubMed]

184. Park, S.J.; Kostic, M.; Dyson, H.J. Dynamic Interaction of Hsp90 with Its Client Protein p53. *J. Mol. Biol.* 2011, 411, 158–173. [CrossRef]

185. Rudiger, S.; Freund, S.M.; Veprintsev, D.B.; Fersht, A.R. CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. *Proc. Natl. Acad. Sci. USA* 2002, 99, 11085–11090. [CrossRef]

186. Walerych, D.; Gutkowska, M.; Klejman, M.P.; Wawrzynow, B.; Tracz, Z.; Wiech, M.; Zylicz, M.; Zylicz, A. ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein. *J. Biol. Chem.* 2010, 285, 32020–32028. [CrossRef]

187. Denney, A.S.; Weems, A.D.; McMurray, M.A. Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast. *G3* 2021, 11, jkab230. [CrossRef]

188. Woodford, M.R.; Backe, S.J.; Wengert, L.A.; Dunn, D.M.; Bourboula, D.; Mollapour, M. Hsp90 chaperone code and the tumor suppressor VHL cooperatively regulate the mitotic checkpoint. *Cell Stress Chaperones* 2021, 26, 965–971. [CrossRef]

189. Centini, R.; Tsang, M.; Iwata, T.; Park, H.; Delrow, J.; Margineantu, D.; Iritani, B.M.; Gu, H.; Liggitt, H.D.; Kang, J.; et al. Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation. *PLoS ONE* 2018, 13, e0197973. [CrossRef]